2016
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLOS ONE 2016, 11: e0161257. PMID: 27526117, PMCID: PMC4985133, DOI: 10.1371/journal.pone.0161257.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineAdjusted vaccine effectivenessTimeliness of vaccinationVaccine effectivenessPost boosterConjugate vaccinePneumococcal diseaseVaccine-type invasive pneumococcal diseaseType invasive pneumococcal diseaseIndirect cohort methodOverall vaccine effectivenessPneumococcal conjugate vaccinationSpecific vaccine effectivenessNumber of dosesYears of ageResidual casesTime of infectionConjugate vaccinationPCV13 serotypesPCV7 serotypesFirst doseIPD casesUnvaccinated childrenVaccination status
2015
Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLOS ONE 2015, 10: e0131494. PMID: 26132078, PMCID: PMC4488910, DOI: 10.1371/journal.pone.0131494.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenes, BacterialGermanyHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ProgramsImmunologic SurveillanceInfantInfant, NewbornMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesRNA, Ribosomal, 16SSerogroupSerotypingStreptococcus pneumoniaeVaccinationConceptsEarly vaccination periodPneumococcal conjugate vaccinationInvasive pneumococcal diseaseVaccination periodConjugate vaccinationPCV7 serotypesIPD casesPneumococcal diseaseQuellung methodSerotype distributionChildhood pneumococcal conjugate vaccinationNon-vaccinated age groupsAge groupsGerman National Reference CenterPre-vaccination periodSerotype 1Streptococcus pneumoniae isolatesNational Reference CenterMicrobiological diagnostic laboratorySerotype 10AInfant vaccinationVaccine serotypesSerotype 19ASeparate age groupsPneumoniae isolatesIncrease of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infectious Diseases 2015, 15: 207. PMID: 25940580, PMCID: PMC4424534, DOI: 10.1186/s12879-015-0941-9.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePenicillin non-susceptible isolatesNon-PCV13 serotypesNon-susceptible isolatesSerotype 15AVaccination periodSurveillance of IPDClonal complexesChildhood pneumococcal conjugate vaccinationGerman National Reference CenterEarly vaccination periodHigher-valent vaccinesPneumococcal conjugate vaccinationNational Reference CenterConclusionsThe prevalenceConjugate vaccinationSerotype 23BPneumococcal diseaseChildhood vaccinationVaccination eraSurveillance periodSerogroups 23BackgroundThis studyReference centerVaccination formulations
2013
Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from IPD in Children and Adults in Germany
van der Linden M, Winkel N, Küntzel S, Farkas A, Perniciaro S, Reinert R, Imöhl M. Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from IPD in Children and Adults in Germany. PLOS ONE 2013, 8: e60848. PMID: 23593324, PMCID: PMC3621884, DOI: 10.1371/journal.pone.0060848.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotypes 6BSerogroup 6 isolatesSerotypes 6ASerotype 6CChildhood pneumococcal conjugate vaccinationSerotype 6DPneumococcal conjugate vaccinationPneumococcal conjugate vaccineLow resistance ratesSerotype 6C isolatesConjugate vaccinationPCV periodPCV7 vaccinationPneumococcal diseaseConjugate vaccineMultilocus sequence typingChildhood vaccinationResistance ratesVaccinationPrevalenceSequence typingStatistical significanceAntibiotic resistanceSerotype 6D.